Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ginkgo Leaf Dropping Pills and Huperzine A Injection Combined With Median Nerve Electrical Stimulation in the Treatment of Cognitive Impairment After Brain Injury
NCT06704334Phase 4Recruiting
- Sponsor
- Wanbangde Pharmaceutical Holding Group
- Start
- Apr 2024
- Primary completion
- Dec 2026
- Modality
- Nucleic Acid-Directed Small Molecules, Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of Huperzine A, ginkgo biloba extract in cognitive impairment, sponsored by Wanbangde Pharmaceutical Holding Group. Started Apr 2024; status: recruiting.
02
Drugs
Huperzine Aginkgo biloba extract
03
Conditions
cognitive impairment
Beyond the preview
Go deeper on NCT06704334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06704334.